# idiopathic hypersomnia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/idiopathic-hypersomnia

> 1 upcoming FDA catalyst in idiopathic hypersomnia: TAK-360 (TAK) on November 2026 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 12, 2026 | [LUMRYZ (lumryz) topline data readout](https://sec-api.dev/pdufa/lumryz) | ALKS | idiopathic hypersomnia | completed, positive | "On May 12, 2026, the Company announced positive topline results from REVITALYZSM, a double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ® (sodium oxybate) extended-release oral suspension compared to placebo in adults with idiopathic hypersomnia." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/alks-20260512.htm)) |
| Nov 2026 to Feb 2027 | [TAK-360 topline data readout](https://sec-api.dev/pdufa/tak-360) | TAK | Idiopathic Hypersomnia | scheduled | "NCT06812078 (A Study of TAK-360 in Adults With Idiopathic Hypersomnia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812078)) |
| November 2026 | [Alks 2680 dose 1 primary completion](https://sec-api.dev/pdufa/alks-2680) | ALKS | Idiopathic Hypersomnia | scheduled | "NCT06843590 (A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06843590)) |
| Nov 2026 to Feb 2027 | [Alks 2680 dose 1 topline data readout](https://sec-api.dev/pdufa/alks-2680) | ALKS | Idiopathic Hypersomnia | scheduled | "NCT06843590 (A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Alkermes, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06843590)) |
| November 2026 | [TAK-360 primary completion](https://sec-api.dev/pdufa/tak-360) | TAK | Idiopathic Hypersomnia | scheduled | "NCT06812078 (A Study of TAK-360 in Adults With Idiopathic Hypersomnia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812078)) |

## Drugs

- [LUMRYZ (lumryz)](https://sec-api.dev/pdufa/lumryz) (ALKS)
- [TAK-360](https://sec-api.dev/pdufa/tak-360) (TAK)
- [Alks 2680 dose 1](https://sec-api.dev/pdufa/alks-2680) (ALKS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/idiopathic-hypersomnia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "idiopathic hypersomnia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/idiopathic-hypersomnia

```bibtex
@misc{secapidev_indications_idiopathic_hypersomnia_20261116,
  title        = {idiopathic hypersomnia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/idiopathic-hypersomnia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_idiopathic_hypersomnia_20261116","title":"idiopathic hypersomnia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/idiopathic-hypersomnia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
